Targeting STAT3 and STAT5 in Cancer

Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur...

Full description

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:	Biology, life sciences Research & information: general ADAM17 adoptive T cell therapy AKT androgens apoptosis autoimmune disease autosomal-dominant hyper IgE syndrome Bone Marrow Failure Syndromes breast cancer cancer cancer models cancer progression cancer-stem cell CD38 CD4+ T cells CD8+ T cells cell cycle cell hierarchy chaperones chemotherapy resistance cirrhosis colon cancer companion animals comparative oncology cytokine cytokine receptor signaling dynamic programming endoplasmic reticulum (ER) stress epidermal growth factor receptor (EGF-R) ERK1/2 escape mechanisms gain-of-function mutation glioblastoma glioma growth hormone insensitivity syndrome heat shock proteins hedging hematopoietic cancers hepatitis C virus (HCV) hepatocellular carcinoma (HCC) hepatocyte nuclear factor 4 alpha (HNF4A) immune check point immune suppression immunosuppression immunotherapy inflammation inflammation associated cancer inflammatory hepatocellular adenomas interleukin-6 JAK JAK family of protein tyrosine kinases JAK2 V617F knockout lipopolyplex lung cancer lymphocytes lymphoma M2 macrophages melanoma meta-analysis metalloprotease metastasis microRNA-122 (miR-122) mitochondria MPN mTOR multiple myeloma mutations myeloid cells myeloid leukemia n/a nanoparticle neoplastic stem cells NGS NK cells nuclear factor erythroid 2-related factor 2 (NRF2) nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling ovarian cancer oxidative stress (OS) PD-L1 PEI pharmacological inhibitor pharmacological inhibitors polyethylenimine post-decision state variable prolactin proliferation prostate cancer RHOA risk management S3I-1757 SH2 domain shedding signal transducer and activator of transcription signal transducer and activator of transcription 3 (STAT3) siRNA delivery siRNA/RNAi small-molecule inhibitors solid cancers stabilization STAT STAT transcription factors STAT3 STAT3 inhibitor XIII STAT5 STAT5 signaling STAT5B signaling stem/progenitor cells stemness T-cell large granular lymphocytic leukemia T-cell leukemia T-cell prolymphocytic leukemia T-cells T-PLL targeted therapy targeting therapeutic targeting therapy resistance trans-signaling transaction costs tumor microenvironment tumor necrosis factor alpha (TNFα) tumor suppression tumor-associated macrophages tumor-immune cell interactions tumorigenesis tyrosine kinase 2 unfolded protein response (UPR)
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Internet

Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication

Targeting STAT3 and STAT5 in Cancer

Internet

Similar Items